Roth starts CG Oncology at buy, cites anticipated FDA filing [Seeking Alpha]
CG Oncology, Inc. (CGON)
Company Research
Source: Seeking Alpha
Roth said Phase 3 results for the drug could be released at the Society of Urologic Oncology meeting in early December. It sees an approximately 15% upside and 10% downside based on the stock's closing price on Aug. 26. The firm believes cretostimogene's tolerability differentiates it from competing products and could help it gain market share in the BCG-unresponsive, high-risk NMIBC market. It also sees the product having a 50% probability of success in treating intermediate-risk NMIBC. Roth estimates the market opportunity for cretostimogene in treating incident cases of BCG-unresponsive, high-risk NMIBC and intermediate-risk NMIBC could exceed $2B. “However, our worldwide sales estimate does not include prevalent NMIBC patients, which is believed to be twice as large as the incident population according to various KOLs and CGON's market research,” Roth added. Roth set a price target for the stock at $65. CG Oncology held its initial public offering in January. Recommen
Show less
Read more
Impact Snapshot
Event Time:
CGON
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CGON alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CGON alerts
High impacting CG Oncology, Inc. news events
Weekly update
A roundup of the hottest topics
CGON
News
- CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual Meeting [Yahoo! Finance]Yahoo! Finance
- CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual MeetingGlobeNewswire
- CG Oncology Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]Yahoo! Finance
- CG Oncology, Inc. (NASDAQ: CGON) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.MarketBeat
- CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business UpdatesGlobeNewswire
CGON
Earnings
- 11/12/24 - Beat
CGON
Sec Filings
- 11/12/24 - Form SC
- 11/12/24 - Form 10-Q
- 11/12/24 - Form 8-K
- CGON's page on the SEC website